Divergent single cell transcriptome and epigenome alterations in ALS and FTD patients with C9orf72 mutation.

TitleDivergent single cell transcriptome and epigenome alterations in ALS and FTD patients with C9orf72 mutation.
Publication TypeJournal Article
Year of Publication2023
AuthorsLi J, Jaiswal MK, Chien J-F, Kozlenkov A, Jung J, Zhou P, Gardashli M, Pregent LJ, Engelberg-Cook E, Dickson DW, Belzil VV, Mukamel EA, Dracheva S
JournalNat Commun
Volume14
Issue1
Pagination5714
Date Published2023 Sep 15
ISSN2041-1723
KeywordsAmyotrophic Lateral Sclerosis, C9orf72 Protein, Epigenome, Frontotemporal Dementia, Humans, Mutation, Transcriptome
Abstract

A repeat expansion in the C9orf72 (C9) gene is the most common genetic cause of amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD). Here we investigate single nucleus transcriptomics (snRNA-seq) and epigenomics (snATAC-seq) in postmortem motor and frontal cortices from C9-ALS, C9-FTD, and control donors. C9-ALS donors present pervasive alterations of gene expression with concordant changes in chromatin accessibility and histone modifications. The greatest alterations occur in upper and deep layer excitatory neurons, as well as in astrocytes. In neurons, the changes imply an increase in proteostasis, metabolism, and protein expression pathways, alongside a decrease in neuronal function. In astrocytes, the alterations suggest activation and structural remodeling. Conversely, C9-FTD donors have fewer high-quality neuronal nuclei in the frontal cortex and numerous gene expression changes in glial cells. These findings highlight a context-dependent molecular disruption in C9-ALS and C9-FTD, indicating unique effects across cell types, brain regions, and diseases.

DOI10.1038/s41467-023-41033-y
Alternate JournalNat Commun
PubMed ID37714849
PubMed Central IDPMC10504300
Grant ListR01 AG067151 / AG / NIA NIH HHS / United States